[{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Streeterville","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2025","type":"Collaboration","leadProduct":"NP-300","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Napo Therapeutics \/ Streeterville","highestDevelopmentStatusID":"5","companyTruncated":"Napo Therapeutics \/ Streeterville"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napo Therapeutics \/ SPRIM Global investments","highestDevelopmentStatusID":"6","companyTruncated":"Napo Therapeutics \/ SPRIM Global investments"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Napo Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Napo Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Mytesi (crofelemer) is a plant-based drug extracted & purified from the red bark sap. It is being developed for short bowel syndrome with intestinal failure.

                          Product Name : Mytesi

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 19, 2025

                          Lead Product(s) : Crofelemer

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The collaboration aims to advance the clinical development of NP-300 drug product candidate for the symptomatic relief of diarrhea and dehydration in cholera patients.

                          Product Name : NP-300

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Undisclosed

                          February 18, 2025

                          Lead Product(s) : NP-300

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Streeterville

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The company's initial focus is on clinical development and future registration in Europe of Mytesi (crofelemer) for two debilitating rare disease target indications: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal fail...

                          Product Name : Mytesi

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 02, 2023

                          Lead Product(s) : Crofelemer

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : SPRIM Global investments

                          Deal Size : $58.8 million

                          Deal Type : Private Placement

                          blank